Seguir
Gilles Buchwalter
Gilles Buchwalter
Dana-Farber Cancer Institute, Harvard Medical School
Dirección de correo verificada de dfci.harvard.edu
Título
Citado por
Citado por
Año
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer
R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ...
Clinical cancer research 20 (7), 1757-1767, 2014
6712014
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff
Nature reviews Clinical oncology 12 (10), 573-583, 2015
5892015
Ets ternary complex transcription factors
G Buchwalter, C Gross, B Wasylyk
Gene 324, 1-14, 2004
4782004
Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations
R Jeselsohn, JS Bergholz, M Pun, MI Cornwell, W Liu, A Nardone, T Xiao, ...
Cancer cell 33 (2), 173-186. e5, 2018
2332018
Net‐targeted mutant mice develop a vascular phenotype and up‐regulate egr‐1
A Ayadi, H Zheng, P Sobieszczuk, G Buchwalter, P Moerman, K Alitalo, ...
The EMBO journal, 2001
1532001
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
R Jeselsohn, MI Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, ...
Proceedings of the National Academy of Sciences 114 (22), E4482-E4491, 2017
1102017
Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter
G Fiucci, S Beaucourt, D Duflaut, A Lespagnol, P Stumptner-Cuvelette, ...
Proceedings of the National Academy of Sciences 101 (10), 3510-3515, 2004
942004
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
SW Fanning, R Jeselsohn, V Dharmarajan, CG Mayne, M Karimi, ...
Elife 7, e37161, 2018
882018
Regulation of MCP-1 chemokine transcription by p53
K Hacke, B Rincon-Orozco, G Buchwalter, SY Siehler, B Wasylyk, ...
Molecular cancer 9, 1-12, 2010
802010
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
Z Mounir, JM Korn, T Westerling, F Lin, CA Kirby, M Schirle, G McAllister, ...
Elife 5, e13964, 2016
762016
TMPRSS2: ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation
Z Mounir, F Lin, VG Lin, JM Korn, Y Yu, R Valdez, OH Aina, G Buchwalter, ...
Oncogene 34 (29), 3815-3825, 2015
712015
PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells
G Buchwalter, MM Hickey, A Cromer, LM Selfors, RN Gunawardane, ...
Cancer cell 23 (6), 753-767, 2013
712013
The ternary complex factor Net regulates cell migration through inhibition of PAI-1 expression
G Buchwalter, C Gross, B Wasylyk
Molecular and cellular biology, 2005
702005
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
Y Kuang, B Siddiqui, J Hu, M Pun, MI Cornwell, G Buchwalter, ...
NPJ breast Cancer 4 (1), 22, 2018
382018
Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells
J Van Riggelen, G Buchwalter, U Soto, JDC Arce, H Zur Hausen, ...
Journal of Biological Chemistry 280 (5), 3286-3294, 2005
352005
The ternary complex factor net is downregulated by hypoxia and regulates hypoxia-responsive genes
C Gross, G Buchwalter, H Dubois-Pot, E Cler, H Zheng, B Wasylyk
Molecular and Cellular Biology 27 (11), 4133-4141, 2007
292007
The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling
K Nakade, H Zheng, G Ganguli, G Buchwalter, C Gross, B Wasylyk
Molecular and cellular biology 24 (3), 1132-1142, 2004
262004
Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response
RM Jeselsohn, L Werner, MM Regan, A Fatima, L Gilmore, LC Collins, ...
PLoS One 8 (5), e64225, 2013
192013
Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer
RM Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ...
CANCER RESEARCH 73, 2013
42013
Abstract P3-05-09: Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance
M Nguyen, G Buchwalter, F Luo, L Garraway, M Brown, R Jeselsohn
Cancer Research 76 (4_Supplement), P3-05-09-P3-05-09, 2016
22016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20